National Institutes of Health (NIH) Uses American Recovery and Reinvestment Act (ARRA) Funding to Advance Scientific Research

BIO recognizes the importance of appropriate consideration and use of clinical pharmacogenomic data by the FDA to ensure that this information is used appropriately to improve healthcare outcomes. BIO represents companies that are involved specifically with pharmacogenomics, therefore, welcome the opportunity to work with the FDA as the Agency develops guidance on clinical pharmacogenomic studies through all phases of product research and development.

Read the comments (122 KB PDF)